Tecentriq Disappoints In Post-Surgery Bladder Cancer
Fails To Hit Disease-Free Survival
Executive SummaryFailure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.
You may also be interested in...
Biosimilars will take a bigger bite out of revenues in 2020 but Roche should score some hits from its broad pipeline.
Vydaqel saw its uptake take off in the US last year. UK’s NICE to pass judgement on cost effectiveness by June.
CAR-T therapies are groundbreaking in clinical terms, but have hit barriers in uptake. Can BMS’s challenger go one better than Yescarta and Kymriah?